Axsome Therapeutics (AXSM) Income from Continuing Operations (2015 - 2026)
Axsome Therapeutics (AXSM) reported Income from Continuing Operations of 64542000.0 for Q1 2026, down 8.63% on a YoY basis from 70640222.64 in Q1 2025, and down 125.43% sequentially from 28631000.0 in Q4 2025.
Axsome Therapeutics (AXSM) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Income from Continuing Operations data on file, last reported at 64542000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 8.63% year-over-year to 64542000.0; the trailing twelve-month figure through Mar 2026 stood at 188375000.0 (up 32.31% YoY), and the FY2025 full-year result was 183206000.0, up 36.21% from the prior year.
- Income from Continuing Operations declined to 64542000.0 in Q1 2026, from 28631000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11238000.0 in Q1 2023 to a low of 98636000.0 in Q4 2023.
- A 5-year average of 56552823.53 and a median of 61241000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 81.04% in 2022 and plunged 508.27% in 2024, its largest moves.
- Tracing AXSM's Income from Continuing Operations over 5 years: stood at 61241000.0 in 2022, then tumbled by 61.06% to 98636000.0 in 2023, then gained by 24.05% to 74912000.0 in 2024, then soared by 61.78% to 28631000.0 in 2025, then tumbled by 125.43% to 64542000.0 in 2026.
- Business Quant data shows AXSM's Income from Continuing Operations at 64542000.0 in Q1 2026, 28631000.0 in Q4 2025, and 47229000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -64.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.54 Mn |
| Dec 31, 2025 | -28.63 Mn |
| Sep 30, 2025 | -47.23 Mn |
| Jun 30, 2025 | -47.97 Mn |
| Mar 31, 2025 | -59.41 Mn |
| Dec 31, 2024 | -74.91 Mn |
| Sep 30, 2024 | -64.60 Mn |
| Jun 30, 2024 | -79.35 Mn |
| Mar 31, 2024 | -68.36 Mn |
| Dec 31, 2023 | -98.64 Mn |
| Sep 30, 2023 | -62.20 Mn |
| Jun 30, 2023 | -67.19 Mn |
| Mar 31, 2023 | -11.24 Mn |
| Dec 31, 2022 | -61.24 Mn |
| Sep 30, 2022 | -44.82 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -39.63 Mn |
| Dec 31, 2021 | -35.12 Mn |
| Sep 30, 2021 | -219.49 Mn |
| Jun 30, 2021 | -218.58 Mn |